“This moderate but critical shift highlights that we are making progress and that we need to continue to accelerate our efforts,” said Julie Fleshman, JD, MBA, president and CEO of the Pancreatic Cancer Action Network. “I am extremely grateful to our supporters and the amazing patients that participate in clinical trials helping to make this progress possible.” Read more . . .
The five-year survival rate for the disease increased, moving from 8 to 9 percent.* This is the third straight year that the five-year survival rate has climbed.